Acoramidis significantly reduces the risk of all-cause and cardiovascular mortality in patients with ATTR-CM through month 54 – BridgeBio
BridgeBio Pharma, Inc. presented long-term efficacy and safety data from the ATTRibute-CM open-label extension (OLE) trial, demonstrating sustained clinical benefit of acoramidis through Month 54 in patients with… read more.
